Literature DB >> 26056050

Learning curve and intra/interobserver agreement of transient elastography in chronic hepatitis C patients with or without HIV co-infection.

Hugo Perazzo1, Flavia F Fernandes2, João Carlos Soares3, Juliana Fittipaldi3, Sandra W Cardoso3, Beatriz Grinsztejn3, Valdiléa G Veloso3.   

Abstract

BACKGROUND AND OBJECTIVES: Liver stiffness measurement (LSM) by transient elastography has been validated as a noninvasive method to stage liver fibrosis. Few studies have evaluated the learning curve of this method and its reproducibility has led to controversy results. We aimed to evaluate the intra- and interobserver agreement of transient elastography as well as its learning curve for definition of an experimented operator.
METHODS: We retrospectively analyzed 922 examinations performed in 544 patients during a training program of transient elastography. Patients with chronic hepatitis C with or without HIV co-infection that had two examinations by the training operator (intraobserver analysis; n=125) or examination by both training and experimented operators (interobserver analysis; n=151) in the same day were included. LSM was converted to METAVIR score: <7.1 as F0F1, 7.1-9.4 as F2, 9.5-12.4, as F3 and >12.4 kPa as F4.
RESULTS: The overall intra- and interobserver intraclass correlation coefficient [ICC 95% CI] were 0.926 (0.901-0.951) and 0.912 (0.885-0.939), respectively. Measurements were correlated [Spearman's] in intra- [0.906, P<0.0001] and interobserver [0.907, P<0.0001] analysis. Reliability values [kappa (SE)] were k=0.74 (0.09) and k=0.85 (0.08) for fibrosis stages F ≥ 2 and k=0.77 (0.09) and k=0.75 (0.08) for cirrhosis in intra- and interobserver analysis, respectively. Agreement was improved when operator's experience was higher than 100 exams. However, it was observed discordance for fibrosis staging between examinations in a quarter of patients.
CONCLUSION: Although there was a considerable discrepancy on fibrosis staging between examinations and a small power, transient elastography had an acceptable reproducibility in our population. Performance of at least 100 examinations should be used to define an experimented operator.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26056050     DOI: 10.1016/j.clinre.2015.04.004

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  5 in total

Review 1.  Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.

Authors:  Rodolfo Castro; Hugo Perazzo; Beatriz Grinsztejn; Valdilea G Veloso; Chris Hyde
Journal:  Int J Hepatol       Date:  2015-11-29

2.  Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard.

Authors:  Flavia F Fernandes; Hugo Perazzo; Luiz E Andrade; Alessandra Dellavance; Carlos Terra; Gustavo Pereira; João L Pereira; Frederico Campos; Maria L Ferraz; Renata M Perez
Journal:  Biomed Res Int       Date:  2017-09-13       Impact factor: 3.411

3.  Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.

Authors:  Saverio Giuseppe Parisi; Monica Basso; Carlo Mengoli; Renzo Scaggiante; Samantha Andreis; Marzia Maria Franzetti; Anna Maria Cattelan; Daniela Zago; Mario Cruciani; Massimo Andreoni; Sara Piovesan; Giorgio Palù; Alfredo Alberti
Journal:  Ann Gastroenterol       Date:  2017-07-04

Review 4.  Factors That Could Impact on Liver Fibrosis Staging by Transient Elastography.

Authors:  Hugo Perazzo; Valdilea G Veloso; Beatriz Grinsztejn; Chris Hyde; Rodolfo Castro
Journal:  Int J Hepatol       Date:  2015-12-06

5.  Disc measurement and nucleus calibration in a smoothened lumbar model increases the accuracy and efficiency of in-silico study.

Authors:  Jingchi Li; Chen Xu; Xiaoyu Zhang; Zhipeng Xi; Shenglu Sun; Ke Zhang; Xiaoyang Fang; Lin Xie; Yang Liu; Yueming Song
Journal:  J Orthop Surg Res       Date:  2021-08-13       Impact factor: 2.359

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.